{"id":2843,"date":"2019-10-08T20:20:23","date_gmt":"2019-10-08T18:20:23","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2843"},"modified":"2023-12-04T09:20:37","modified_gmt":"2023-12-04T08:20:37","slug":"digestive-tract-pathology","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/translational-medicine-area\/digestive-system-diagnostics-pharmacogenetics-care-support-and-clinical-prevention-program-2\/digestive-tract-pathology\/","title":{"rendered":"Digestive tract pathology"},"content":{"rendered":"\n

\n\t\tDigestive tract pathology\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\tThe\u00a0group has a wide range of interests, including various gastrointestinal system diseases (gastrointestinal bleeding, inflammatory bowel diseases and diverticular disease) and focusses on colorectal cancer.
\nIts extensive experience in clinical trials and surgical studies is complemented with collaborations with basic research groups, creating valuable knowledge in the field, in order to optimise both chemotherapy treatments and surgical protocols in patients with rectal cancer.\n

550<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"gastritis_helicobacter_-_intermed_mag\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tGastrointestinal bleeding
\nInflammatory bowel disease
\nDiverticular disease\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Mils K, Mir\u00f3 M, Farran L, Videla S, Alba E, Estremiana F, Bettonica C, Aranda H. A pilot randomized controlled trial on the utility of gastric conditioning in the prevention of esophagogastric anastomotic leak after Ivor Lewis esophagectomy<\/strong>. Int. J. Surg. 2022;106106921-106921. doi:10.1016\/j.ijsu.2022.106921.<\/p>\n

Trenti L, Biondo S, Espin Basany E, Barrios O, Sanchez JL, Landaluce A, Bermejo E, Garcia Martinez MT, Alias D, Jimenez F, Alonso A, Manso MB, Kreisler E, THDLIGA RCT Study G. Transanal Hemorrhoidal Dearterialization with Mucopexy vs Vessel Sealing Device Hemorrhoidectomy for Grade III-IV Hemorrhoids: Long-term Outcomes from the THDLIGA-RCT Randomized Clinical Trial<\/strong>. Dis Colon Rectum. 2022;doi:10.1097\/DCR.0000000000002272.<\/p>\n

Climent M, Frago R, Cornell\u00e0 N, Serrano M, Kreisler E, Biondo S. Prognostic factors for complications after loop ileostomy reversal<\/strong>. Tech Coloproctol. 2022;26(1):45-52. doi:10.1007\/s10151-021-02538-0.<\/p>\n

Golda T, Lazzara C, Sorribas M, Soriano A, Frago R, Alrasheed A, Kreisler E, Biondo S. Combined endoscopic-laparoscopic surgery (CELS) can avoid segmental colectomy in endoscopically unremovable colonic polyps: a cohort study over 10 years<\/strong>. Surg Endosc. 2022;36(1):196-205. doi:10.1007\/s00464-020-08255-3.<\/p>\n

Rodr\u00edguez Alonso L, Rodr\u00edguez Moranta F, Maisterra S, Botargues JM, Berrozpe A, Ru\u00edz Cerulla A, Suris G, Camps B, Gornals JB, Guardiola J. The EPAGE guidelines are not an effective strategy for managing colonoscopies during the COVID-19 pandemic. Gastroenterol<\/strong>. Hepatol. 2022;45(1):9-17. doi:10.1016\/j.gastrohep.2020.11.020.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

18ACL129. AN OBSERVATIONAL PROSPECTIVE LONG-TERM EXPOSURE REGISTRY OF ADJULT PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS<\/strong>. Budget: 186800. 2018- . PI: Guardiola Cap\u00f3n, Jordi.<\/p>\n

18ACL053. ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN’S DISEASE<\/strong>. Budget: 76000. 2018-2024. PI: Guardiola Cap\u00f3n, Jordi.<\/p>\n

19ACL036. Estudio multic\u00e9ntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensi\u00f3n abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con enfermedad de crohn que respondan al tratamiento de inducci\u00f3n en los estudios M16-006, M15-991 o que hayan completado el estudio M15-989<\/strong>. Budget: 40722. 2019- . PI: Guardiola Cap\u00f3n, Jordi.<\/p>\n

PUB22004. Estudio prospectivo y multic\u00e9ntrico sobre factores cl\u00ednico-biol\u00f3gicos predictivos de Diverticulitis CR\u00d3nica de colon (DICRO). Hospital Universitario de Bellvitge<\/strong>. Budget: 19450. 2022-2025. PI: Climent Agust\u00edn, Marta.<\/p>\n

20PSJ019. Estudio prospectivo y multic\u00e9ntrico sobre factores cl\u00ednico-biol\u00f3gicos predictivos de Diverticulitis CR\u00d3nica de colon (DICRO)<\/strong>. ASOCIACION ESPA\u00d1OLA DE CIRUJANOS. Budget: 10000. 2020-2022. PI: Biondo Aglio, Sebastiano.<\/p>\n\t\t\t\t\tTechnology transfer<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT043-Lipogel t\u00f3pico rectal que comprende un agente anest\u00e9sico y un agente antiinflamatorio no esteroideo para el alivio del dolor
\nIP: Maria Jos\u00e9 Linares
\nEP 15382416\nLicense: Rectal topical lipogel comprising an anesthetic agent and a nonsteroidal anti-inflamatoty agent for pain relief
\nPI: Dra. Maria Jos\u00e9 Linares\n\t\t\t\t\"Sebastiano-biondo\"\n

\n\t\tBiondo Aglio, Sebastiano\n\t<\/h4>\n

\n\t\t\n\t\tsbiondo@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\"Sebastiano-biondo\"\n

\n\t\tBiondo Aglio, Sebastiano\n\t<\/h4>\n

\n\t\t\n\t\tsbiondo@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar\"\n

\n\t\tBotargues Bote, Josep Maria\n\t<\/h4>\n

\n\t\t\n\t\tjbotargues@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Ricardo-Frago-Montanuy\"\n

\n\t\tFrago Montanuy, Ricardo\n\t<\/h4>\n

\n\t\t\n\t\tjfrago@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Alexandra-Ruiz-Cerulla\"\n

\n\t\tRuiz Cerulla, Alexandra\n\t<\/h4>\n\t\t\t\t\"Jordi-Guardiola-Capon\"\n

\n\t\tGuardiola Capon, Jordi\n\t<\/h4>\n

\n\t\t\n\t\tjguardiola@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar\"\n

\n\t\tCliment Agustin, Marta\n\t<\/h4>\n

\n\t\t\n\t\tmcliment@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tRELATED LINKS\n\t<\/h4>\n

\n\t\t\n\t\t@sbiondo60\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@MartaCliment105\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@JordiGuardiolac\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t